Pharmaceuticals Analysts discuss the implications of Merck’s Sotatercept’s Phase III STELLAR data on treatment of Pulmonary Arterial Hypertension (PAH) on an Analyst/Industry conference call to be held on March 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Opko Health Surges as Merck Considers Deal
- Opko Health enters exclusive worldwide license agreement with Merck
- Sotatercept data supports bullish view of Merck cardio franchise, says Jefferies
- Merck cardiovascular franchise set for ‘resurgence,’ says Mizuho
- Gossamer Bio downgraded to Market Perform from Outperform at Raymond James